AXGN (54) CNMD (62) ITGR (67) LIVN (61) ⌘ Pro Terminal →

TransMedics Group Inc. (TMDX) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell TMDX stock right now?

TransMedics Group Inc. (TMDX) currently earns a Roarable Rating of C+ (Hold — HOLD) with 69/100 RQD Confidence. Solid 60% profit margin (18% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.

Q: What is TMDX's 12-month price target and RQD AI Jury consensus?

TMDX's 12-month base price target is $70.44 (range $54.94 to $163.8), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$67.12 +0.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

TransMedics Group Inc. (TMDX) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $2.33B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+4.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TMDX)Realized 20D OHLCV Swing Band: ±10.6%

RSI-14 MOMENTUMOVERSOLD (<32)

28.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.50>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE7% OF RANGE

L: $60$67.12H: $156

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (60% profit margin and healthy balance-sheet cushion).

Factor Grade: BRQD 15 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on TMDX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (75)

18.1% ROIC with 59.9% gross margin and 5.74% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 3.50 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (63)

26/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like TMDX

✓Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (TMDX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TMDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.41%▼ SUPPORT BREAKDOWN

2026-10-30O $67.59H $67.75L $64.64C $67.12VOL 898.5K

RES: $111.3SUP: $75.69SMA50: $81.65SMA200: $94.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TMDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TMDX Butterfly Map → + Track TMDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

2.8%/yr Implied 5Y Growth

vs. +37.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TMDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TMDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TMDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TMDX)

Health Care Rank #100 of 1016 ⚔️ AXGN vs TMDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TMDX vs. AXGN, CNMD, ITGR, LIVN)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TransMedics Group Inc. (TMDX) ranks #100 by composite RQD confidence (69/100, grade C+) and #233 by equity capitalization ($2.33B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. TMDX currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TMDX ACTIVE TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	Benchmark Subject
AXGN Axogen Inc.	D+	54/100	—	74.3%	-2.6%	+0.77%	$2.96B	/axgn-vs-tmdx →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-tmdx →
ITGR Integer Holdings Corporation	C+	67/100	41.8x	27.0%	6.0%	-0.02%	$4.30B	/itgr-vs-tmdx →
LIVN LivaNova PLC	C-	61/100	—	67.7%	17.3%	+0.73%	$4.48B	/livn-vs-tmdx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001756262

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TransMedics Group Inc. (TMDX) reported GAAP revenue of $605.5M (+37.1% vs. FY2024 revenue of $441.5M , and +150.6% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $192.8M, and free cash flow of $133.6M (+265.0% YoY). On the balance sheet, TMDX closed FY2025 with $1.07B in total assets against $0 in total debt (Altman Z-Score: 3.50, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$605.5M	$190.3M	$192.8M	$133.6M	$1.07B	—
FY2024 (FY)	2024-12-31	$441.5M	$35.5M	$48.8M	-$80.9M	$804.1M	—
FY2023 (FY)	2023-12-31	$241.6M	-$25.0M	-$13.0M	-$13.0M	—	—

3. TMDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, TransMedics Group Inc. (NASDAQ: TMDX) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $67.12 (+0.33% 1D, market cap $2.33B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, TMDX ranks #100 in composite RQD confidence.

How does TMDX compare to AXGN and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), TMDX carries a Roarable C+ (69/100 RQD), trailing P/E of 12.2x, gross margin of 59.9%, and ROIC of 18.1%. By comparison, AXGN (Axogen Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -2.6%, cap $2.96B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TMDX?

Per TMDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001756262), TransMedics Group Inc. generated $605.5M in revenue (+37.1% YoY), $190.3M in net income, and $133.6M in free cash flow against $1.07B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TMDX trading relative to its 50-day, 200-day, and 52-week technical levels?

TMDX last traded at $67.12 (+0.33% on volume of 991,428 shares), positioning the stock -17.80% below its 50-day simple moving average ($81.65) and -28.96% below its 200-day simple moving average ($94.48). Across its 52-week range of $60.11 to $156.00, TMDX sits at the 7.3% percentile with a 14-day RSI of 28.9 (OVERSOLD (<32)) and an implied next-earnings move of ±10.6% ($60.01 to $74.23).

TMDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell TMDX stock right now?

TransMedics Group Inc. (TMDX) currently earns a Roarable Rating of C+ (Hold — HOLD) with 69/100 RQD Confidence. Solid 60% profit margin (18% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.

What is TMDX's 12-month price target and RQD AI Jury consensus?

TMDX's 12-month base price target is $70.44 (range $54.94 to $163.8), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: TMDX RQD Cockpit TMDX 12M Forecast TMDX Earnings & Move TMDX Dividends & DRIP TMDX Insiders & 13F TMDX Whale Options TMDX Profit Sankey TMDX News & Why